The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of exemestane with or without entinostat in women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yusuke, Lee, Min-Jung, Lee, Sunmin, Tomita, Saori, Chumsri, Saranya, Cruickshank, Scott, Ordentlich, Peter, Trepel, Jane B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139687/
https://www.ncbi.nlm.nih.gov/pubmed/27999738
http://dx.doi.org/10.1080/2162402X.2016.1219008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139687/
https://www.ncbi.nlm.nih.gov/pubmed/27999738
http://dx.doi.org/10.1080/2162402X.2016.1219008

Ejemplares similares